Mylan expands oncology portfolio with launch of generic Faslodex® injection
Mylan announced U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic version of AstraZeneca's Faslodex® Injection. Mylan received approval from the FDA for its ANDA for this product, which is used to treat certain types of advanced breast cancer. September 17, 2019